Site notes
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
Sender's message:
Sent on Saturday, 2008 Nov 15.
Search anxiety disorder
Click on the following url to view complete results in pubmed. (Results may change over time.)
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0veS5aBTNh4j2hPnwEkr58A2Do_YCIHhU33RRoNNKAzR5x9JMAQ3w1YInUlkHkA&WebCubbyUser=0pQ9vMKCA8dOMKzOnwROdDeo%40990F039F91E782A1_0002SID
To unsubscribe from these e-mail updates click on the following url
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0paoDa1HAmxNF8hjWvpkCUw6TFeZ9pz2CMbF_7_w5fKkCADcO&WebCubbyUser=0pQ9vMKCA8dOMKzOnwROdDeo%40990F039F91E782A1_0002SID
==================== Entrez pubmed Results ======================
Items 1 - 5 of 34
1: Biol Psychiatry. 2008 Nov 10; [Epub ahead of print]
Childhood Predictors of Adult Attention-Deficit/Hyperactivity Disorder: Results
from the World Health Organization World Mental Health Survey Initiative.
Lara C, Fayyad J, Graaf RD, Kessler RC, Aguilar-Gaxiola S, Angermeyer M,
Demytteneare K, Girolamo GD, Haro JM, Jin R, Karam EG, Lepine JP, Mora ME, Ormel
J, Posada-Villa J, Sampson N.
Department of Psychiatry, Autonomous University of Puebla, Puebla, Mexico.
BACKGROUND: Although it is known that childhood attention-deficit/hyperactivity
disorder (ADHD) often persists into adulthood, childhood predictors of this
persistence have not been widely studied. METHODS: Childhood history of ADHD and
adult ADHD were assessed in 10 countries in the World Health Organization World
Mental Health Surveys. Logistic regression analysis was used to study
associations of retrospectively reported childhood risk factors with adult
persistence among the 629 adult respondents with childhood ADHD. Risk factors
included age; sex; childhood ADHD symptom profiles, severity, and treatment;
comorbid child/adolescent DSM-IV disorders; childhood family adversities; and
child/adolescent exposure to traumatic events. RESULTS: An average of 50% of
children with ADHD (range: 32.8%-84.1% across countries) continued to meet
DSM-IV criteria for ADHD as adults. Persistence was strongly related to
childhood ADHD symptom profile (highest persistence associated with the
attentional plus impulsive-hyperactive type, odds ratio [OR] = 12.4, compared
with the lowest associated with the impulsive-hyperactive type), symptom
severity (OR = 2.0), comorbid major depressive disorder (MDD; OR = 2.2), high
comorbidity (>/=3 child/adolescent disorders in addition to ADHD; OR = 1.7),
paternal (but not maternal) anxiety mood disorder (OR = 2.4), and parental
antisocial personality disorder (OR = 2.2). A multivariate risk profile of these
variables significantly predicts persistence of ADHD into adulthood (area under
the receiving operator characteristic curve = .76). CONCLUSIONS: A substantial
proportion of children with ADHD continue to meet full criteria for ADHD as
adults. A multivariate risk index comprising variables that can be assessed in
adolescence predicts persistence with good accuracy.
PMID: 19006789 [PubMed - as supplied by publisher]
2: Cyberpsychol Behav. 2008 Nov 12; [Epub ahead of print]
Internet-Based Cognitive-Behavioral Therapy for Bulimia Nervosa: A Controlled
Study.
Fernandez-Aranda F, Nunez A, Martinez C, Krug I, Cappozzo M, Carrard I, Rouget
P, Jimenez-Murcia S, Granero R, Penelo E, Santamaria J, Lam T.
Department of Psychiatry, University Hospital of Bellvitge, Barcelona, Spain.,
CIBER Fisiopatologia Obesidad y Nutricion (CIBERObn), Instituto Salud Carlos
III, Spain.
Abstract The object of this study was to examine the effectiveness of an
Internet-based therapy (IBT) for bulimia nervosa (BN) as compared to a waiting
list (WL). Sixty-two female BN patients, diagnosed according to DSM-IV criteria,
were assigned to either the IBT or a WL. The control participants (WL) were
matched to the IBT group in terms of age, duration of the disorder, number of
previous treatments, and severity of the disorder. Assessment measures included
the EDI, SCL-90-R, BITE, the TCI-R, and other clinical and psychopathological
indices, which were administrated before and after the treatment. Considering
the IBT, while the mean scores were lower at the end of the treatment for some
EDI scales (bulimic, interpersonal distrust, maturity fears, and total score)
and the BITE symptomatology subscale, the mean BMI was higher at posttherapy.
Predictors of good IBT outcome were higher scores on the EDI perfectionism scale
and EAT and a higher minimum BMI. Drop-out (after IBT 35.5% of cases) was
related to higher SCL-anxiety scores, a lower hyperactivity, a lower minimum
BMI, and lower TCI-reward dependence scores. At the end of the treatment,
bingeing and vomiting abstinence rates differed significantly between the two
groups. Results suggest that an online self-help approach appears to be a valid
treatment option for BN when compared to a WL control group, especially for
people who present a lower severity of their eating disorder (ED) symptomatology
and some specific personality traits.
PMID: 19006463 [PubMed - as supplied by publisher]
3: Depress Anxiety. 2008 Nov 12; [Epub ahead of print]
Escitalopram in the treatment of major depressive disorder in primary-care
settings: an open-label trial.
Chokka P, Legault M.
Grey Nuns Community Hospital, Edmonton, Canada.
Background: The present trial was designed to assess the efficacy and safety of
escitalopram prescribed to patients seeking treatment of major depressive
disorder (MDD) in a Canadian primary-care setting. Methods: Investigators
(mainly primary-care physicians) enrolled patients with MDD from their daily
practice. Patients were treated with escitalopram (flexible dose 10-20 mg/day)
for up to 24 weeks. Efficacy assessments included the Montgomery-Asberg
Depression Rating Scale (MADRS), the Clinical Global Impression-Improvement and
-Severity scales (CGI-I, CGI-S), the Patient Global Evaluation (PGE), and the
Medical Outcome Study 36-item Short Form (SF-36). Results: Out of the 647
patients enrolled, 461 (71%) completed 24 weeks of treatment. The most common
reason for discontinuation was adverse events (10%). The mean MADRS score
decreased from 30.7 at baseline to 10.9 at the end of 24 weeks (last observation
carried forward, LOCF). Remission (MADRS</=12) was achieved by 65.5% of patients
(LOCF). Symptom improvements were confirmed by global ratings of improvement
made by physicians (CGI-I) as well as patients PGE. There was improvement on all
dimensions of the SF-36, suggesting an overall improvement in quality of life.
Conclusions: Escitalopram was well tolerated, safe, and efficacious.
Escitalopram can be used with confidence to treat patients with MDD in Canadian
primary-care settings. Depression and Anxiety 0:1-9, 2008. (c) 2008 Wiley-Liss,
Inc.
PMID: 19006260 [PubMed - as supplied by publisher]
4: Depress Anxiety. 2008 Nov 12; [Epub ahead of print]
Evidence-based guidelines for interpretation of the Panic Disorder Severity
Scale.
Furukawa TA, Katherine Shear M, Barlow DH, Gorman JM, Woods SW, Money R, Etschel
E, Engel RR, Leucht S.
Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City
University Graduate School of Medical Sciences, Nagoya, Japan.
Background: The Panic Disorder Severity Scale (PDSS) is promising to be a
standard global rating scale for panic disorder. In order for a clinical scale
to be useful, we need a guideline for interpreting its scores and their changes,
and for defining clinical change points such as response and remission. Methods:
We used individual patient data from two large randomized controlled trials of
panic disorder (total n=568). Study participants were administered the PDSS and
the Clinical Global Impression (CGI)-Severity and -Improvement. We applied
equipercentile linking technique to draw correspondences between PDSS and
CGI-Severity, numeric changes in PDSS and CGI-Improvement, and percent changes
in PDSS and CGI-Improvement. Results: The interpretation of the PDSS total score
differed according to the presence or absence of agoraphobia. When the patients
were not agoraphobic, score ranges 0-1 corresponded with "Normal," 2-5 with
"Borderline," 6-9 with "Slightly ill," 10-13 with "Moderately ill," and 14 and
above with "Markedly ill." When the patients were agoraphobic, score ranges 3-7
meant "Borderline ill," 8-10 "Slightly ill," 11-15 "Moderately ill," and 16 and
above "Markedly ill." The relationship between PDSS change and CGI-Improvement
was more linear when measured as percentile change than as numeric changes, and
was indistinguishable for those with or without agoraphobia. The decrease by
75-100% was considered "Very much improved," that by 40-74% "Much improved," and
that by 10-39% "Minimally improved." Conclusion: We propose that "remission" of
panic disorder be defined by PDSS scores of five or less and its "response" by
40% or greater reduction. Depression and Anxiety 0:1-8, 2008. (c) 2008
Wiley-Liss, Inc.
PMID: 19006198 [PubMed - as supplied by publisher]
5: Stress. 2008 Nov 13;:1 [Epub ahead of print]
Modulation of stress by imidazoline binding sites: Implications for psychiatric
disorders.
Smith KL, Jessop DS, Finn DP.
Department of Pharmacology and Therapeutics, NCBES Neuroscience Cluster,
National University of Ireland, Galway, Ireland.
In this review, we present evidence for the involvement of imidazoline binding
sites (IBS) in modulating responses to stress, through central control of
monoaminergic and hypothalamo-pituitary-adrenal (HPA) axis activity.
Pharmacological and physiological evidence is presented for differential effects
of different IBS subtypes on serotoninergic and catecholaminergic pathways
involved in control of basal and stress-stimulated HPA axis activity. IBS
ligands can modulate behavioural and neuroendocrine responses in animal models
of stress, depression and anxiety, and a body of evidence exists for alterations
in central IBS expression in psychiatric patients, which can be normalised
partially or fully by treatment with antidepressants. Dysfunction in
monoaminergic systems and the HPA axis under basal and stress-induced activation
has been extensively reported in psychiatric illnesses. On the basis of the
literature, we suggest a potential therapeutic role for selective IBS ligands in
the treatment of depression and anxiety disorders.
PMID: 19006007 [PubMed - as supplied by publisher]